D-0577-2020 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0577-2020 was initiated by Pfizer Inc. on Nov 27, 2019 and is designated Class II. Reason for recall: Labeling: Incorrect or Missing Lot and/or expiration date. The recall status is terminated (terminated Jan 14, 2022). Affected quantity: 77,100 syringes.

Recall details

Product Type
Drugs
Report Date
Dec 18, 2019
Initiation Date
Nov 27, 2019
Termination Date
Jan 14, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
77,100 syringes

Product description

25% Dextrose Injection, USP 2.5 grams (250 mg/mL) 10 mL Single-dose, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-1775-10

Reason for recall

Labeling: Incorrect or Missing Lot and/or expiration date.

Distribution pattern

Nationwide within the United States including Puerto Rico.

Code information

Lot #: 80-292-EV, 1AUG2019 on carton. Expiration date printed on syringe is 1AUG2021 which is incorrect.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0577-2020
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0577-2020. Report a data issue: hello@regdatalab.com.